association between pneumonia mortality risk and inequities in access to care and preventive services. The United Nations General Assembly Millennium Development Goal number 4 (MDG4), aimed at reducing the under-5 (U5) mortality rate by two-thirds between 1990 and 2015, has in recent years become a rallying point for activities that are directed against childhood pneumonia. UNICEF and WHO declared pneumonia to be ''the forgotten killer of children'' in 2006 [4] , and, for the first time in history, the World Health Assembly passed a resolution recognizing pneumonia as the world's leading infectious killer of children on 21 May 2010 [5] , thus making pneumonia a global health priority.
Although significant progress has been made in reducing mortality in children ,5 years of age in the last decade, it is now recognized that MDG4 can only be achieved by an intensified effort to reduce childhood pneumonia deaths. Following a meeting of experts convened by WHO and UNICEF in Geneva in 2007 [6] to discuss the best prospects for pneumonia control, a Global Action Plan for Pneumonia (GAPP), based on a 3-pronged platform of prevention, protection, and treatment (PPT) [7] was launched on the first World Pneumonia Day on 2 November 2009 in New York. Accelerated implementation of efforts aimed at improved nutrition, reduced exposure to indoor air pollution, increased vaccine coverage, and effective antimicrobial treatment combined with innovative operational and basic research aimed at filling the gaps can prevent most childhood pneumonia deaths. A high level of commitment from local and international stakeholders will be required for successful implementation of this new initiative for the control of pneumonia deaths.
Early studies of the etiology of pneumonia undertaken in several developing countries have shown that Streptococcus pneumoniae is the most important cause of pneumonia in young children [8] . Blood culture for isolation of bacteria is the common tool for bacteriological diagnosis of pneumonia but the method is insensitive and suboptimal. Studies in which lung aspirates were used in the 1970s and early 1980s have shown that S. pneumoniae accounted for about 50% of incriminated bacterial isolates [9] and that it and Haemophilus influenzae type b (Hib) were the most frequently detected bacterial causes of pneumonia. The ambitious epidemiologic studies of acute lower respiratory infections (ALRI) undertaken across 10 sites in developing countries in the 1980s by the US Board of Science and Technology for International Development (BOSTID) also established pneumococcus and H. influenzae as the commonest bacterial causes of pneumonia. In addition, these studies confirmed respiratory syncytial virus (RSV) as the most common viral cause of lower respiratory tract infections. There was, however, a great deal of diversity recorded across the sites [10] . More recently, GAVI Alliance's PneumoADIP and Hib Initiative extended surveillance for pneumococcus, Hib, and other bacterial causes of pneumonia and meningitis to several developing countries with substantial success [11] . This type of country-specific and/or regional data has turned out to be crucial to financial and programmatic decision making at country level. Haemophilus species and S. pneumoniae are also responsible for a variety of other disease states such as otitis media, sepsis, and meningitis.
Pneumococcus causes an estimated burden of 14.5 million episodes of serious illness in children under 5 years old and 826 000 childhood deaths each year worldwide [12] . It consists of over 91 serotypes, all of which are potentially capable of causing pneumococcal disease. However, serotypes causing invasive pneumococcal disease in children are limited in number and vary in ranking order over time. The most frequently reported include serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, all of which are included in the heptavalent pneumococcal conjugate vaccine (PCV-7). Others include serotypes in PCV-7 plus serotypes 1, 5, and 7F (PCV-10) and serotypes in PCV-10 plus serotypes 3, 6A, and 19A (PCV-13). Clinically significant antimicrobial resistance is restricted to seven serotypes (6A, 6B, 9V, 14, 19A, 19F, and 23F), all of which are contained in currently available PCVs with the potential for overall reduction of antimicrobial-resistant pneumococci. Serotypes also vary by geographic area; thus, vaccine coverage against the serotypes in Europe and the United States is different from that in developing countries. Studies have shown that the burden of pneumococcal disease is 10-fold to 20-fold higher in developing countries than any that has been recorded in Europe and the United States and is up to 40-fold higher among infants with HIV infection [13] . Despite the less-than-optimal serotype match, currently available pneumococcal conjugate vaccines can prevent 50-80% of all childhood pneumococcal disease worldwide based on the global distribution of 7-13 serotypes, all of which are contained in these vaccines [12] .
Until recently, capability for defining the full spectrum of etiology of pneumonia has been limited because of poor sensitivity of diagnostic methods. Current case management guidelines, particularly the Integrated Management of Childhood Illness (IMCI) strategy, which includes a standardized protocol for management of children with suspected pneumonia, were developed on the basis of evidence that most pneumoniarelated deaths in infants and children are due to S. pneumoniae and H. influenzae. The evidence is from studies conducted in non-HIV-endemic populations, prior to the development of preventive interventions such as the Hib and pneumococcal conjugate vaccines [14] . Moreover, increasing resistance to current antibiotics and the widening spectrum of microbial causes of pneumonia because of HIV infection are a continuing challenge to effective treatment of pneumonia, particularly at the community level, where laboratory confirmation of diagnosis is less than optimal. Thus, primary prevention of bacterial pneumonia is an attractive public health option. Improvements in living conditions (reduction of overcrowding, undernutrition, and atmospheric pollution) can be expected to reduce the incidence of bacterial pneumonia in children in developing countries, but these improvements may be difficult to achieve except as part of trends in global development. In the short term, vaccination offers the best prospect for reducing the incidence of pneumonia. It is now generally accepted that Hib and pneumococcal vaccines can prevent pneumonia and have a major effect on pneumonia mortality, by as much as 50%, in developing countries.
Polysaccharide vaccines are poorly immunogenic in infants; however, when they are conjugated with a suitable protein carrier, the resulting polysaccharide-protein conjugate vaccines have been shown to be immunogenic in infants, to induce immunological memory, and to protect against nasopharyngeal colonization. This provides additional benefits by blocking carriage and transmission, leading to indirect protection of unvaccinated infants and adults by herd immunity. Routine use of Hib conjugate vaccine in childhood immunization programs has led to virtual elimination of Hib disease even in settings with less than optimal immunization delivery systems [15, 16] . Early efficacy trials of PCVs in the United States [17] , South Africa [18] , and The Gambia [19] showed that the vaccine is safe, immunogenic, and highly efficacious against pneumococcal disease when given to infants and toddlers. PCV was shown to be protective against pneumococcal disease in patients with HIV infection in South Africa.
A randomized controlled trial of a 9-valent pneumococcal conjugate vaccine in The Gambia showed that the vaccine can, in addition, produce a reduction of 15% in all-cause hospital admissions and a reduction of 16% in all-cause mortality, demonstrating for the first time that this was a life-saving vaccine and making prevention of pneumococcal disease one of the highest priorities for improving child survival [19] . Over the last decade, the availability of these vaccines has had a major impact on invasive pneumococcal disease and pneumonia in developed countries [20] . Introduction of PCV for routine use in developing countries has been slow for several reasons, including vaccine cost, supply constraints, and confusion about the appropriate valency for developing countries, as well as a lack of disease burden data, poor vaccine delivery system, and some concerns about serotype replacement.
However, with funding from GAVI Alliance and the recent launch of the Advanced Market Commitment (AMC), access to pneumococcal conjugate vaccines is being accelerated for use in resource-poor countries. PCVs of expanded serotype coverage (including serotypes 1 and 5, which are highly prevalent in developing countries) have been developed and are being introduced following WHO's prequalification process to ensure vaccine standards and safety. Pneumococcal cross-protecting common protein vaccines are being developed for possible containment of serotype replacement. Some efforts have also been directed at development of pneumococcal whole-cell vaccines that may be more affordable in developing countries. While there is a need to closely monitor the introduction and impact of these vaccines, if the GAVI-supported introductions of PCV in developing countries are as successful as they have been in the United States, it can be expected there will be dramatic reductions in pneumococcal pneumonia and the associated deaths over the next decade.
By 2010 Hib immunization had been introduced in 66 (92%) of 72 GAVI-eligible countries [21] and PCVs are being introduced increasingly into childhood immunization programs. It is likely that widespread immunization with Hib and PCVs will lead to changes in proportions of pathogen-specific etiology of pneumonia in developing countries. For example, nonbacterial respiratory disease such as viral pneumonia caused by RSV or influenza virus and pulmonary tuberculosis may become more prevalent in these regions with consequent failure of standard antibiotic therapy [14] . Additionally, HIV infection is now widespread and has important effects on the frequency of pneumonia and the spectrum of associated pathogens. Despite the impact of these vaccines, it is important to recognize that not all pneumonia is caused by pneumococcus, and not all pneumococcal pneumonia will be prevented by the current vaccines. Etiology studies taking advantage of new technology are required for a more precise description of microbial causes of pneumonia. These studies are needed also to gain knowledge of potential changes in bacterial antibiotic sensitivities to better inform decisions around vaccine development, introduction, and the algorithms for treatment of pneumonia in the field.
At The Bill & Melinda Gates Foundation our pneumonia strategy is focused on reducing childhood deaths due to pneumonia. To achieve this, it is essential for the global health community to have a better understanding of the etiology of severe pneumonia. In particular, it is of crucial strategic importance to carefully assess and catalog the pathogens responsible for pneumonia over the next several years as vaccines are being introduced: A deeper understanding of the etiology of childhood pneumonia and changes in pathogen prevalence following vaccine introductions will provide important information for case management and the prioritization of research and development of future interventions. Taking advantage of the recent advances in molecular analysis for pathogen detection and using standardized case definitions and methods across seven countries in Africa and Asia, the Pneumonia Etiology Research for Child Health (PERCH) project, with support from The Bill & Melinda Gates Foundation, will provide valuable insight into changes in the broader pathogen landscape that need to be anticipated in the years ahead. Preliminary data are anticipated from all seven sites that are participating in PERCH as early as 2012.
In addition, the activities in this project will provide invaluable information to complement other strategic initiatives of our Pneumonia Program, which in general aspire to eliminate inequity in the pneumonia burden by improving access to existing interventions, filling the knowledge gaps, and innovating for better future interventions for attainment of desirable impact. Because the project provides a mutually independent approach to measuring the burden of disease, concordance with results from pathogen-specific clinical research programs will prove especially convincing. While gathering important information on the distribution of known bacterial and viral pathogens, this program will also provide important data on risk factors. The sample bank will be a major resource for future research efforts, including the identification of unknown or emerging viral pathogens and evaluation of promising diagnostic tests, requiring specimens from well characterized sources. The isolation and testing of bacterial strains for their antimicrobial resistance will complement the learning agenda now under way by providing additional local data from developing countries on pathogen sensitivity to antibiotics. As treatment is expanded there are concerns that health gains will be eroded by the development of resistance, and it is important to have baseline data now to be able to track and respond to increases in antibiotic resistance of the pathogens that cause pneumonia.
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